Atara Biotherapeutics Earnings Perspective: Return On Capital Employed
Portfolio Pulse from Benzinga Insights
Atara Biotherapeutics reported Q1 sales of $1.23 million and a loss of $74.77 million, a 0.27% decrease from last quarter. The company posted a negative ROCE of -1.15%, suggesting inefficient capital allocation.
May 23, 2023 | 2:54 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Atara Biotherapeutics reported a Q1 loss of $74.77 million and a negative ROCE of -1.15%, indicating potential inefficiency in capital allocation.
Atara Biotherapeutics reported a loss in Q1 and a negative ROCE of -1.15%, which suggests that the company may not be effectively allocating its capital. This could negatively impact the stock price in the short term as investors may perceive the company as less efficient compared to its peers.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100